SLANG Worldwide Announces Q4 and Year-End 2023 Financial Results
SLANG Worldwide Announces Q4 and Year-End 2023 Financial Results
Achieved adjusted gross profit margin1 of approximately 51% in Q4 FY2023 and 52% in FY2023
實現調整後的毛利率1 FY2023 第四季度約爲 51%，FY2023 爲 52%
Operating Expenses decreased approximately 19% in Q4 FY2023 and 21% in FY2023
FY2023 第四季度的運營支出下降了約19％，FY2023 的運營支出下降了21％
Increased annual adjusted gross profit1 by 6%
年度調整後毛利增加1 上漲6％
Launched wholesale offering in Vermont to capitalize on increase in licensed retail businesses
在佛蒙特州推出批發服務，以利用持牌零售業務的增長
Toronto, Ontario--(Newsfile Corp. - April 12, 2024) - SLANG Worldwide Inc. (CNSX: SLNG) (OTCQB: SLGWF) ("SLANG" or the "Company"), a leading global cannabis consumer packaged goods (CPG) company with a diversified portfolio of popular brands, today released financial results for the three and twelve months ended December 31, 2023. All figures in this press release are stated in Canadian dollars unless otherwise noted.
安大略省多倫多--（Newsfile Corp.，2024年4月12日）——擁有多元化流行品牌組合的全球領先的大麻消費包裝製品（CPG）公司SLANG Worldwide Inc.（CNSX：SLNG）（OTCQB：SLGWF）（“SLANG” 或 “公司”）今天公佈了截至2023年12月31日的三個月和十二個月的財務業績。除非另有說明，否則本新聞稿中的所有數字均以加元表示。
"In 2023, we took a deliberate approach to advancing our strategy of profitable growth, creating a leaner, more nimble SLANG. As a result, we ended the year with increased gross profit, higher margins, and lower operating expenses which resulted in significantly lower total comprehensive loss and lower adjusted EBITDA loss," commented John Moynan, Chief Executive Officer of SLANG. "With the fourth quarter historically our seasonally lowest revenue quarter, we took the opportunity to further fortify our business and refine our product offering, which will help us make meaningful progress on the path to profitability."
“2023年，我們採取了深思熟慮的方法來推進我們的盈利增長戰略，創造了一個更精簡、更靈活的俚語。因此，我們在年底實現了毛利增加、利潤率提高和運營費用降低，這導致綜合虧損總額大幅降低，調整後的息稅折舊攤銷前利潤虧損降低。” SLANG首席執行官約翰·莫伊南評論道。“由於第四季度是歷史上收入最低的季度，我們藉此機會進一步鞏固了業務並完善了我們的產品供應，這將幫助我們在盈利道路上取得有意義的進展。”
Moynan continued, "Throughout 2023, we continued to set ourselves apart from other cannabis players by strategically identifying and advancing opportunities in both our core and emerging markets to build our brand and drive continued financial growth. Initiatives such as our disposable and large-format vaporizers in Colorado, the build-out of our wholesale channel in Vermont, and the expansion of our THC-Free product portfolio have proved successful and will be key contributors to our ongoing growth. Looking to 2024, I believe that we are well positioned to outperform the market as we continue to identify opportunities to increase shareholder value as part of our strategic review."
莫伊南繼續說：“在整個2023年，我們通過戰略性地確定和推進核心和新興市場的機會，建立我們的品牌並推動持續的財務增長，從而繼續將自己與其他大麻企業區分開來。事實證明，我們在科羅拉多州的一次性和大幅面蒸發器、在佛蒙特州擴大批發渠道以及擴大我們的無四氫大麻酚產品組合等舉措是成功的，並將成爲我們持續增長的關鍵因素。展望2024年，我相信隨着我們在戰略審查中繼續尋找增加股東價值的機會，我們完全有能力跑贏市場。”
Full Year 2023 Financial and Operational Summary
2023 年全年財務和運營摘要
- Revenue from continuing operations for the year ended December 31, 2023 ("FY 2023") was $35.68 million, compared with $38.19 million in the year ended December 31, 2022 ("FY 2022"), representing a 7% decrease year-over-year. The reduction was primarily driven by a decrease of $2.65 million in our Distribution sales and a decrease of $1.27 million in Emerging Market sales, partially offset by an increase of $0.70 million in Core Market sales and an increase of $0.66 million in e-commerce sales. Within the Core Market segment, the Company experienced growth in Vermont, with sales increasing by $3.06 million, which is offset by a reduction of $2.36 million in sales in Colorado.
- Gross profit of $18.62 million (52% gross margin) in FY 2023, compared with $16.45 million (43% gross margin) in FY 2022, representing a 13% increase in gross profit and a 9% increase in gross margin year-over-year. Gross profit before fair value of biological assets was $18.68 million (52% gross margin) in FY 2023, compared with $17.62 million (46% gross margin) in FY 2022, representing a 6% increase in gross profit and a 6% increase in gross margin year-over-year.
- Operating expenses of $24.61 million in FY 2023, compared with $31.33 million in FY 2022, representing a 21% decrease year-over-year. The reduction was primarily driven by a decrease in depreciation and amortization, share based payments, salaries and wages and consulting and subcontractors.
- Total comprehensive loss of $19.59 million in FY 2023, compared with $29.65 million in FY 2022, representing a 34% decrease year-over-year. The reduction was primarily driven by a decrease in operating expenses of $6.73 million and an increase in gross profit of $2.17 million.
- EBITDA1 of ($3.05 million) in FY 2023, compared with ($8.71 million) in FY 2022. The improvement in EBITDA is primarily attributable to a $2.14 million increase in gross profit (excluding depreciation costs), and a reduction of $3.52 million in operating expenses (excluding depreciation) such as share based payments, insurance, salaries and wages, and consulting and subcontractors.
- Adjusted EBITDA1 of ($1.90 million) in FY 2023, compared with ($3.65 million) in FY 2022. The improvement in Adjusted EBITDA is primarily attributable to an increase of $1.02 million in gross profit before fair value adjustments of biological assets (excluding depreciation costs), and a reduction of $0.73 million in operating expenses (excluding depreciation expenses, expected credit losses and share based payments).
- $9.04 million in cash and restricted cash on December 31, 2023, compared to $11.92 million on December 31, 2022. Additionally, for the twelve months ended December 31, 2023, cash flows used in continuing operating activities was ($2.62 million), compared to cash flows used in continuing operating activities of ($3.13 million) for the twelve months ended December 31, 2022, an improvement of $0.51 million.
- Various SLANG subsidiaries filed for the Employee Retention Tax Credit ("ERTC")2 with the Internal Revenue Service ("IRS") in April 2023. During FY 2023, the Company received $1.63 million in ERTCs and $0.09 million in interest on ERTCs.
- In June 2023, the Company launched a new two-gram disposable cartridge in Colorado. For the year ended December 31, 2023, the sales of these products totaled approximately $1.62 million.
- The Company built a new wholesale revenue stream in Vermont as more Vermont retailers received retail licenses. In FY 2023, wholesale sales to Vermont retailers reached $1.04 million.
- 截至2023年12月31日的財年（“2023財年”）的持續經營收入爲3568萬美元，而截至2022年12月31日的財年（“2022財年”）爲3,819萬美元，同比下降7％。下降的主要原因是我們的分銷銷售額減少了265萬美元，新興市場銷售額減少了127萬美元，但部分被核心市場銷售額增長70萬美元和電子商務銷售額增加66萬美元所抵消。在覈心市場領域，公司在佛蒙特州的銷售額增長了306萬美元，但科羅拉多州銷售額減少的236萬美元抵消了這一增長。
- 2023財年的毛利爲1,862萬美元（毛利率爲52％），而2022財年的毛利率爲1,645萬美元（毛利率爲43％），毛利同比增長13％，毛利率增長9％。2023財年，生物資產不計公允價值的毛利爲1,868萬美元（毛利率爲52％），而2022財年爲1762萬美元（毛利率爲46％），毛利率同比增長6％，毛利率同比增長6％。
- 2023財年的運營支出爲2461萬美元，而2022財年爲3,133萬美元，同比下降21％。減少的主要原因是折舊和攤銷、基於股份的付款、工資和工資以及諮詢和分包商的減少。
- 2023財年的綜合虧損總額爲1,959萬美元，而2022財年爲2965萬美元，同比下降34％。減少的主要原因是運營支出減少了673萬美元，毛利增加了217萬美元。
- EBITDA1 2023財年爲（305萬美元），而2022財年爲871萬美元。息稅折舊攤銷前利潤的改善主要歸因於毛利增長了214萬美元（不包括折舊成本），以及運營費用（不包括折舊）減少了352萬美元（不包括折舊），例如基於股份的付款、保險、工資和工資以及諮詢和分包商。
- 調整後 EBITDA1 2023財年爲（190萬美元），而2022財年爲365萬美元。調整後息稅折舊攤銷前利潤的改善主要歸因於生物資產公允價值調整前的毛利增加了102萬美元（不包括折舊成本），以及運營費用（不包括折舊費用、預期信貸損失和基於股份的付款）減少了73萬美元。
- 2023年12月31日的現金和限制性現金爲904萬美元，而2022年12月31日爲1192萬美元。此外，在截至2023年12月31日的十二個月中，用於持續經營活動的現金流爲（262萬美元），而截至2022年12月31日的十二個月中用於持續經營活動的現金流爲（313萬美元），增長了51萬美元。
- 多家SLANG子公司申請了員工留用稅收抵免（“ERTC”）2 2023 年 4 月加入美國國稅局（“IRS”）。在2023財年，公司獲得了163萬美元的ERTC和ERTC的09萬美元利息。
- 2023 年 6 月，該公司在科羅拉多州推出了一款新的兩克一次性墨盒。在截至2023年12月31日的年度中，這些產品的總銷售額約爲162萬美元。
- 隨着越來越多的佛蒙特州零售商獲得零售許可，該公司在佛蒙特州建立了新的批發收入來源。2023財年，佛蒙特州零售商的批發銷售額達到104萬美元。
Recent Corporate Developments
近期企業動態
- In January 2024, the Company announced that it launched its vape brand, O.pen, in Arizona through a strategic partnership with Trulieve Cannabis Corp.
- The Company announced in November 2023 that it has retained PGP Capital Advisors, LLC, to assist in a review of its strategic alternatives.
- In October 2023, SLANG launched sales of its O.pen Sesh, an electric dab rig compatible with 510-thread cartridges and concentrates.
- The Company launched its first line of fast-acting cannabis-infused gummies in July 2023 under its Alchemy Naturals all-natural THC gummy brand at dispensaries across Vermont.
- SLANG launched a brand new O.pen product line in July and started selling two-gram delta-8 all-in-one vaporizers in five different strains.
- 2024年1月，該公司宣佈通過與Trulieve Cannabis Corp的戰略合作伙伴關係，在亞利桑那州推出了其電子煙品牌O.pen。
- 該公司在2023年11月宣佈，已聘請PGP Capital Advisors, LLC，以協助審查其戰略選擇。
- 2023 年 10 月，SLANG 開始銷售其 O.pen Sesh，這是一款兼容 510 個螺紋的彈藥筒和濃縮液的電動輕拍裝置。
- 該公司於2023年7月在佛蒙特州的藥房以其Alchemy Naturals全天然四氫大麻酚軟糖品牌推出了第一系列注入大麻的速效軟糖。
- SLANG於7月推出了全新的O.pen產品線，並開始銷售五種不同菌株的兩克delta-8多合一蒸發器。
Fourth Quarter 2023 Financial Summary
2023 年第四季度財務摘要
- Revenue from continuing operations for the three months ended December 31, 2023 ("Q4 2023") was $7.42 million, compared with $11.78 million for the three months ended December 31, 2022 ("Q4 2022"), representing a 37% decrease year-over-year. The reduction was primarily driven by a decrease of $4.13 million in Core Market sales and a decrease of $0.92 million in Distribution sales, partially offset by an increase of $0.30 million in Emerging Market sales, and an increase of $0.30 million in e-commerce sales. Within the Core Market segment, the Company experienced sales reductions in Vermont of $2.47 million, and in Colorado of $1.66 million.
- Gross profit of $3.80 million (51% gross margin) in Q4 2023, compared with $4.70 million (40% gross margin) in Q4 2022, representing a 19% decrease in gross profit and a 11% increase in gross margin year-over-year. Gross profit before fair value of biological assets was $3.80 million (51% gross margin) in Q4 2023, compared with $5.70 million (48% gross margin) in Q4 2022, representing a 33% decrease in gross profit and a 3% increase in gross margin year-over-year.
- Operating expenses of $6.63 million in Q4 2023, compared with $8.17 million in Q4 2022, representing a 19% decrease year-over-year. The reduction was primarily driven by a decrease in salaries and wages, depreciation and amortization, share based payments, and consulting and subcontractors.
- Total comprehensive loss of $7.45 million in Q4 2023, compared with $16.96 million in Q4 2022, representing a 56% decrease year-over-year. The reduction was primarily driven by a decrease of $14.83 million in impairment and $1.54 million in operating expenses partially offset by higher financing cost and fair value adjustments of $7.26 million and a decrease in gross profit of $0.90 million.
- EBITDA1 of ($2.09 million) in Q4 2023, compared with ($1.82 million) in Q4 2022. The reduction in EBITDA is primarily attributable to a $1.07 million decrease in gross profit (excluding depreciation costs), offset by a reduction of $0.81 million in operating expenses (excluding depreciation) such as salaries and wages, consulting and subcontractors, share based payments, and insurance.
- Adjusted EBITDA1 of ($1.48 million) in Q4 2023, compared with ($0.06 million) in Q4 2022. The reduction in Adjusted EBITDA is primarily attributable to a decrease of $2.07 million in gross profit before fair value adjustments of biological assets (excluding depreciation costs), offset by a reduction of $0.65 million in operating expenses (excluding depreciation expenses, expected credit losses and share based payments).
- 截至2023年12月31日的三個月（“2023年第四季度”）的持續經營業務收入爲742萬美元，而截至2022年12月31日的三個月（“2022年第四季度”）爲1178萬美元，同比下降37％。下降的主要原因是核心市場銷售額減少了413萬美元，分銷銷售額減少了92萬美元，但新興市場銷售額增加30萬美元和電子商務銷售額增加30萬美元部分抵消。在覈心市場領域，該公司在佛蒙特州的銷售額減少了247萬美元，科羅拉多州的銷售額減少了166萬美元。
- 2023年第四季度的毛利爲380萬美元（毛利率爲51％），而2022年第四季度爲470萬美元（毛利率爲40％），毛利率同比下降19％，毛利率同比增長11％。2023年第四季度生物資產不計公允價值的毛利爲380萬美元（毛利率爲51％），而2022年第四季度爲570萬美元（毛利率48％），毛利率同比下降33％，毛利率同比增長3％。
- 2023年第四季度的運營支出爲663萬美元，而2022年第四季度爲817萬美元，同比下降19％。減少的主要原因是工資和工資的減少、折舊和攤銷、股份支付以及諮詢和分包商。
- 2023年第四季度的綜合虧損總額爲745萬美元，而2022年第四季度爲1,696萬美元，同比下降56％。減少的主要原因是減值減少了1483萬美元，運營費用減少了154萬美元，部分被融資成本和公允價值調整增加的726萬美元以及毛利減少90萬美元所抵消。
- EBITDA1 2023年第四季度爲（209萬美元），而2022年第四季度爲182萬美元。息稅折舊攤銷前利潤減少的主要原因是毛利減少了107萬美元（不包括折舊成本），但被工資和工資、諮詢和分包商、股份付款和保險等運營支出（不包括折舊）減少的81萬美元所抵消。
- 調整後 EBITDA1 2023年第四季度爲（148萬美元），而2022年第四季度爲（60萬美元）。調整後息稅折舊攤銷前利潤的減少主要是由於生物資產公允價值調整前的毛利減少了207萬美元（不包括折舊成本），但被運營支出（不包括折舊費用、預期信貸損失和基於股份的付款）減少的65萬美元所抵消。
Full Year 2023 Financial Review
2023 年全年財務回顧
The consolidated financial statements were prepared in accordance with IFRS. The following is a selected presentation of the Income Statement for the three and twelve months ended December 31, 2023.
合併財務報表是按照《國際財務報告準則》編制的。以下是截至2023年12月31日的三個月和十二個月損益表的精選列報方式。
| (In thousands of Canadian dollars except per share data and percentages) | For the three months ended | For the twelve months ended | ||||||||||
| 31-Dec-23 | 31-Dec-22 | 31-Dec-23 | 31-Dec-22 | |||||||||
| Net Operating Revenue From Continuing Operations |
7,419 |
11,777 |
35,682 |
38,189 |
||||||||
| Cost of goods sold | 3,618 |
6,077 |
17,007 |
20,566 |
||||||||
| Gross Profit Before Fair Value Adjustment of Biological Assets |
3,801 |
5,700 |
18,675 |
17,623 |
||||||||
| Realized fair value amounts included in inventory sold | (705) | (1,298) | (2,112) | (2,976) | ||||||||
| Unrealized gain on changes in fair value of biological assets | 700 |
293 |
2,056 |
1,799 |
||||||||
| Gross Profit |
3,796 |
4,695 |
18,619 |
16,446 |
||||||||
| Gross Profit Margin |
51% |
40% |
52% |
43% |
||||||||
| Operating expenses | 6,632 |
8,167 |
24,606 |
31,332 |
||||||||
| Operating Loss | (2,836) | (3,472) | (5,988) | (14,886) | ||||||||
| Other items (Impairment, FV adjustment, FX, gains/losses, taxes, etc.) | (4,616) | (13,483) | (13,597) | (14,768) | ||||||||
| Total Comprehensive Loss | (7,452) | (16,955) | (19,585) | (29,654) | ||||||||
| Earnings Per Share From Continuing Operations | |
|
|
|
||||||||
| Basic | (0.05) | (0.15) | (0.10) | (0.29) | ||||||||
| Diluted | (0.05) | (0.15) | (0.10) | (0.29) | ||||||||
| （以千加元計，每股數據和百分比除外） | 在結束的三個月裏 | 在截至的十二個月中 | ||||||||||
| 12 月 31 日至 23 日 | 12 月 31 日至 22 日 | 12 月 31 日至 23 日 | 12 月 31 日至 22 日 | |||||||||
| 來自持續經營的淨營業收入 |
7,419 |
11,777 |
35,682 |
38,189 |
||||||||
| 銷售商品的成本 | 3,618 |
6,077 |
17,007 |
20,566 |
||||||||
| 生物資產公允價值調整前的毛利 |
3,801 |
5,700 |
18,675 |
17,623 |
||||||||
| 已售庫存中包含的已實現公允價值金額 | (705) | (1,298) | (2,112) | (2,976) | ||||||||
| 生物資產公允價值變動產生的未實現收益 | 700 |
293 |
2,056 |
1,799 |
||||||||
| 毛利 |
3,796 |
4,695 |
18,619 |
16,446 |
||||||||
| 毛利率 |
51% |
40% |
52% |
43% |
||||||||
| 運營費用 | 6,632 |
8,167 |
24,606 |
31,332 |
||||||||
| 營業虧損 | (2,836) | (3,472) | (5,988) | (14,886) | ||||||||
| 其他項目（減值、FV 調整、外匯、收益/虧損、稅收等） | (4,616) | (13,483) | (13,597) | (14,768) | ||||||||
| 綜合損失總額 | (7,452) | (16,955) | (19,585) | (29,654) | ||||||||
| 持續經營的每股收益 | |
|
|
|
||||||||
| 基本 | (0.05) | (0.15) | (0.10) | (0.29) | ||||||||
| 稀釋 | (0.05) | (0.15) | (0.10) | (0.29) | ||||||||
| (In thousands of Canadian dollars except percentages) | For the three months ended | For the twelve months ended | ||||||||||
| 31-Dec-23 | 31-Dec-22 | 31-Dec-23 | 31-Dec-22 | |||||||||
| Net Operating Revenue From Continuing Operations |
7,419 |
11,777 |
35,682 |
38,189 |
||||||||
| Cost of Goods Sold | 3,618 |
6,077 |
17,007 |
20,566 |
||||||||
| Realized fair value amounts included in inventory sold | (705) | (1,298) | (2,112) | (2,976) | ||||||||
| Unrealized gain on fair value of biological assets | 700 |
293 |
2,056 |
1,799 |
||||||||
| Cost of Goods Sold |
3,623 |
7,082 |
17,063 |
21,743 |
||||||||
| Gross Profit |
3,796 |
4,695 |
18,619 |
16,446 |
||||||||
| Gross Profit Margin |
51% |
40% |
52% |
43% |
||||||||
| Gross Profit before FV adjustment |
3,801 |
5,700 |
18,675 |
17,623 |
||||||||
| Gross Profit Margin before FV adjustment |
51% |
48% |
52% |
46% | ||||||||
| （以千加元計，百分比除外） | 在結束的三個月裏 | 在截至的十二個月中 | ||||||||||
| 12 月 31 日至 23 日 | 12 月 31 日至 22 日 | 12 月 31 日至 23 日 | 12 月 31 日至 22 日 | |||||||||
| 來自持續經營的淨營業收入 |
7,419 |
11,777 |
35,682 |
38,189 |
||||||||
| 售出商品的成本 | 3,618 |
6,077 |
17,007 |
20,566 |
||||||||
| 已售庫存中包含的已實現公允價值金額 | (705) | (1,298) | (2,112) | (2,976) | ||||||||
| 生物資產公允價值的未實現收益 | 700 |
293 |
2,056 |
1,799 |
||||||||
| 售出商品的成本 |
3,623 |
7,082 |
17,063 |
21,743 |
||||||||
| 毛利潤 |
3,796 |
4,695 |
18,619 |
16,446 |
||||||||
| 毛利率 |
51% |
40% |
52% |
43% |
||||||||
| FV 調整前的毛利 |
3,801 |
5,700 |
18,675 |
17,623 |
||||||||
| FV 調整前的毛利率 |
51% |
48% |
52% |
46% | ||||||||
| (In thousands of Canadian dollars) | For the three months ended | For the twelve months ended | | |||||||||
| 31-Dec-23 | 31-Dec-22 | 31-Dec-23 | 31-Dec-22 | | ||||||||
| Total Comprehensive Loss | (7,452) | (16,955) | (19,585) | (29,654) | ||||||||
| EBITDA (Non-IFRS) | (2,087) | (1,822) | (3,052) | (8,710) | ||||||||
| Adjusted EBITDA (Non-IFRS) | (1,478) | (56) | (1,902) | (3,645) | ||||||||
| （以千加元計） | 在結束的三個月裏 | 在截至的十二個月中 | | |||||||||
| 12 月 31 日至 23 日 | 12 月 31 日至 22 日 | 12 月 31 日至 23 日 | 12 月 31 日至 22 日 | | ||||||||
| 綜合虧損總額 | (7,452) | (16,955) | (19,585) | (29,654) | ||||||||
| 息稅折舊攤銷前利潤（非國際財務報告準則） | (2,087) | (1,822) | (3,052) | (8,710) | ||||||||
| 調整後的息稅折舊攤銷前利潤（非國際財務報告準則） | (1,478) | (56) | (1,902) | (3,645) | ||||||||
See the Company's management's discussion and analysis for the three and full year ended December 31, 2023 (the "Q4 2023 MD&A") for a detailed reconciliation of EBITDA and Adjusted EBITDA to Operating Income / (Loss). SLANG's financial statements and the Q4 2023 MD&A are available on SEDAR+ at , and on the Company's Investor Relations website at .
有關息稅折舊攤銷前利潤和調整後息稅折舊攤銷前利潤與營業收入/（虧損）的詳細對賬情況，請參閱公司管理層對截至2023年12月31日的三年和全年財年的討論和分析（“2023年第四季度MD&A”）。SLANG的財務報表和2023年第四季度的管理層與分析可在SEDAR+上查閱，也可以在公司的投資者關係網站上查閱，網址爲。
Non-IFRS Measures
非國際財務報告準則指標
EBITDA, Adjusted EBITDA, adjusted gross profit and adjusted gross margin are non-IFRS financial measures that the Company uses to assess its operating performance. EBITDA is defined as net earnings (loss) before net finance costs, income tax expense (benefit) and depreciation and amortization expense. Management defines Adjusted EBITDA as EBITDA adjusted for other non-cash items such as the impact of unrealized fair values, share based compensation expense, impairments, one-time gains and losses, and one-time revenues and expenses. Management defines adjusted gross profit as gross profit before fair value adjustment of biological assets. Management defines adjusted gross margin as gross margin before fair value adjustment of biological assets. This data is furnished to provide additional information and are non-IFRS measures and do not have any standardized meaning prescribed by IFRS. The Company uses these non-IFRS measures to provide shareholders and others with supplemental measures of its operating performance. The Company also believes that securities analysts, investors and other interested parties, frequently use these non-IFRS measures in the evaluation of companies, many of which present similar metrics when reporting their results. As other companies may calculate these non-IFRS measures differently than the Company, these metrics may not be comparable to similarly titled measures reported by other companies. We caution readers that Adjusted EBITDA should not be substituted for determining net loss as an indicator of operating results, or as a substitute for cash flows from operating and investing activities.
息稅折舊攤銷前利潤、調整後息稅折舊攤銷前利潤、調整後毛利率是公司用來評估其經營業績的非國際財務報告準則財務指標。息稅折舊攤銷前利潤定義爲扣除淨財務成本、所得稅支出（收益）以及折舊和攤銷費用前的淨收益（虧損）。管理層將調整後的息稅折舊攤銷前利潤定義爲經其他非現金項目調整的息稅折舊攤銷前利潤，例如未實現公允價值的影響、基於股份的薪酬支出、減值、一次性損益以及一次性收入和支出。管理層將調整後的毛利定義爲生物資產公允價值調整前的毛利。管理層將調整後的毛利率定義爲生物資產公允價值調整前的毛利率。提供這些數據是爲了提供更多信息，是非國際財務報告準則的指標，不具有《國際財務報告準則》規定的任何標準化含義。公司使用這些非國際財務報告準則指標爲股東和其他人提供其經營業績的補充衡量標準。該公司還認爲，證券分析師、投資者和其他利益相關方在評估公司時經常使用這些非國際財務報告準則指標，其中許多公司在報告業績時給出了相似的指標。由於其他公司計算這些非國際財務報告準則指標的方法可能與公司不同，因此這些指標可能無法與其他公司報告的類似標題的指標進行比較。我們提醒讀者，調整後的息稅折舊攤銷前利潤不應取代將淨虧損確定爲經營業績的指標，或作爲經營和投資活動現金流的替代品。
Conference Call Details
電話會議詳情
Management plans to host an investor conference call on April 12, 2024 at 10:00 am ET to discuss the results.
管理層計劃在美國東部時間2024年4月12日上午10點舉行投資者電話會議，討論結果。
Timing: Friday, April 12, 2024 at 10:00 am ET
Dial In: 1-(888) 440-5983 (US toll-free) or 1-(646) 960-0202 (international)
Conference ID: 6291438
Webcast: A live webcast can be accessed via the Company's website at or
時機： 美國東部時間 2024 年 4 月 12 日星期五上午 10:00
撥入： 1-(888) 440-5983（美國免費電話）或 1-(646) 960-0202（國際）
會議編號： 6291438
網絡直播： 可以通過公司的網站觀看網絡直播，網址爲
About SLANG Worldwide Inc.
SLANG Worldwide Inc. is the industry leader in branded cannabis consumer packaged goods, with a diversified portfolio of five distinct brands and products distributed across the U.S. Operating in 13 legal cannabis markets nationwide, SLANG specializes in acquiring and developing market-proven regional brands, as well as launching innovative new brands to seize global market opportunities and match evolving consumer tastes. The Company has over a decade of experience operating in the nascent and highly regulated cannabis sector, and its partners enjoy the benefits of that experience, with access to the SLANG playbook for successful operations, sales and marketing. Its strong product pipeline from uniquely positioned and scalable brands like O.pen, Alchemy Naturals, Ceres, Firefly, and partnerships with brands like Greenhouse Seed Company have a proven track record of success with the brands consistently ranking among the top performers in the states where SLANG operates. Learn more at slangww.com.
關於 SLANG 全球公司
SLANG Worldwide Inc. 是品牌大麻消費包裝產品的行業領導者，其多元化產品組合由五個不同的品牌和產品組成，分佈在美國的13個合法大麻市場開展業務，專門收購和開發經過市場驗證的區域品牌，並推出創新的新品牌以抓住全球市場機會並滿足不斷變化的消費者口味。該公司在新興且受到嚴格監管的大麻行業擁有十多年的運營經驗，其合作伙伴可以從這種經歷中受益，可以訪問SLANG手冊來成功運營、銷售和營銷。其來自O.pen、Alchemy Naturals、Ceres、Firefly等定位獨特且可擴展的品牌的強大產品線以及與Greenhouse Seed Company等品牌的合作伙伴關係有着良好的成功記錄，這些品牌在SLANG運營的州一直名列前茅。在 slangww.com 上了解更多信息。
To be added to SLANG's email distribution list, please email SLNG@kcsa.com with "SLNG" in the subject.
要加入 SLANG 的電子郵件分發列表，請發送電子郵件至 SLNG@kcsa.com，主題爲 “SLNG”。
Forward-Looking Statements
前瞻性陳述
This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur.
本新聞稿包含構成 “前瞻性陳述” 的陳述。此類前瞻性陳述涉及已知和未知的風險、不確定性和其他因素，這些因素可能導致實際業績、業績或成就或行業發展與此類前瞻性陳述所表達或暗示的預期結果、業績或成就存在重大差異。前瞻性陳述不是歷史事實，通常以 “期望”、“計劃”、“預期”、“相信”、“打算”、“估計”、“項目”、“潛力” 和類似的表述來識別，或者事件或條件 “將”、“將”、“可能”、“可能” 或 “應該” 發生。
Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management of SLANG at this time, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that could cause actual results to differ materially from those expressed or implied in such statements. Investors are cautioned not to put undue reliance on forward-looking statements. Applicable risks and uncertainties include, but are not limited to regulatory risks, risks related to changes in laws, resolutions and guidelines, market risks, concentration risks, operating history, competition, the risks associated with international and foreign operations and the other risks identified under the headings "Risk Factors" in SLANG's Q4 2023 MD&A and other disclosure documents available on the Company's profile on SEDAR+ at . SLANG is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
前瞻性陳述必然基於許多估計和假設，儘管SLANG管理層目前認爲這些估計和假設是合理的，但本質上會受到重大的業務、經濟和競爭風險、不確定性和突發事件的影響，這些風險可能導致實際結果與此類陳述中表達或暗示的結果存在重大差異。提醒投資者不要過分依賴前瞻性陳述。適用的風險和不確定性包括但不限於監管風險、與法律、決議和指導方針變更相關的風險、市場風險、集中風險、經營歷史、競爭、與國際和國外業務相關的風險以及SLANG2023年第四季度MD&A中的 “風險因素” 標題下確定的其他風險，可在SEDAR+的公司簡介中查閱。除非適用法律明確要求，否則SLANG沒有任何義務，也明確表示不打算或義務更新或修改任何前瞻性信息，無論這些信息是由於新信息、未來事件還是其他原因造成的。
Reader Advisory
讀者諮詢
Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
加拿大證券交易所和市場監管機構（該術語在加拿大證券交易所的政策中定義）均不對本新聞稿的充分性或準確性承擔責任。
Company Contact
Mikel Rutherford, CFO
833-752-6499
公司聯繫人
首席財務官米克爾·盧瑟福
833-752-6499
Media and Investor Inquiries
Investors@SLANGww.com
媒體和投資者查詢
Investors@SLANGww.com
KCSA Strategic Communications
Phil Carlson
SLANG@kcsa.com
KCSA 戰略傳播
菲爾·卡爾森
SLANG@kcsa.com
1 See "Non-IFRS Measures"
1 見 “非國際財務報告準則指標”
2 In March 2020, the Coronavirus Aid, Relief, and Economic Security Act was signed into law, providing numerous tax provisions and other stimulus measures, including the ERTC, a refundable tax credit against certain employment taxes. The Taxpayer Certainty and Disaster Tax Relief Act of 2020 and the American Rescue Plan Act of 2021 extended and expanded the availability of the ERTC and the Company qualified for the ERTC in the first three quarters of 2021.
2 2020年3月，《冠狀病毒援助、救濟和經濟安全法》簽署成爲法律，提供了許多稅收條款和其他刺激措施，包括ERTC，針對某些就業稅的可退還稅收抵免。2020年的《納稅人確定性和災難稅收減免法》和2021年的《美國救援計劃法》延長並擴大了ERTC的可用性，公司在2021年前三個季度有資格獲得ERTC。
譯文內容由第三人軟體翻譯。